Overview

Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of gemcitabine and oxaliplatin in treating patients who have locally advanced or metastatic pancreatic cancer.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
GERCOR - Multidisciplinary Oncology Cooperative Group
Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
Treatments:
Gemcitabine
Oxaliplatin
Criteria
DISEASE CHARACTERISTICS: Histologically or cytologically confirmed metastatic or locally
advanced unresectable adenocarcinoma of the pancreas Measurable disease At least 2 cm in
diameter No known brain metastases

PATIENT CHARACTERISTICS: Age: 18 to 75 Performance status: ECOG 0-2 OR Karnofsky 60-100%
Life expectancy: Greater than 12 weeks Hematopoietic: Absolute neutrophil count at least
1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 times
upper limit of normal (ULN) Alkaline phosphatase no greater than 5 times ULN Renal:
Creatinine no greater than 1.5 times ULN Cardiovascular: Adequate cardiac function
Pulmonary: Adequate respiratory function Other: Not pregnant or nursing Fertile patients
must use effective contraception No sensitive neuropathy No other active malignancy No
uncontrolled hypercalcemia No significant medical or psychiatric condition that would
preclude study No psychological, familial, sociological, or geographical condition that
would preclude study

PRIOR CONCURRENT THERAPY: Biologic therapy: No prior immunotherapy Chemotherapy: No prior
chemotherapy Endocrine therapy: No concurrent corticosteroid use except as antiemetic
Radiotherapy: No prior radiotherapy Surgery: Not specified Other: No other concurrent
investigational drugs